Actively Recruiting

Phase 1
Phase 2
Age: 40Years - 80Years
All Genders
NCT06480760

Effects of Carnosine In Patients With Peripheral Arterial Disease Patients

Led by Shahid Baba · Updated on 2025-05-29

144

Participants Needed

3

Research Sites

175 weeks

Total Duration

On this page

Sponsors

S

Shahid Baba

Lead Sponsor

N

National Institutes of Health (NIH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to determine whether carnosine (a food ingredient found in chicken and red meat) supplementation (2 g) for 6 months in participants with non-claudication and claudication peripheral arterial disease (PAD) improves walking ability. Previous studies with heart failure patients have shown that carnosine supplementation increases walking capacity in these patients.

CONDITIONS

Official Title

Effects of Carnosine In Patients With Peripheral Arterial Disease Patients

Who Can Participate

Age: 40Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants between 40-80 years of age
  • White or African American race
  • Literate in English
  • Ankle-Brachial Index (ABI) greater than 0.4 and less than 0.90, measured within 6 weeks before enrollment
  • Willing and able to follow study procedures
  • Able to provide informed consent
Not Eligible

You will not qualify if you...

  • HIV, hepatitis, significant liver disease, anemia, kidney disease requiring dialysis, lung disease requiring home oxygen, or active cancer, as determined by physician
  • Critical limb ischemia with leg amputation or foot ulcers on the affected leg
  • Significant injury within 30 days or vascular intervention on affected leg within 6 months before enrollment
  • Baseline six-minute walk test distance less than 152.0 meters (498 feet) or more than 487.7 meters (1600 feet)
  • Known allergy to L-carnosine
  • Rare metabolic disorders like carnosinemia or carnosinase deficiency
  • Currently enrolled in other clinical trials
  • Previous participation in carnosine supplementation trials
  • Currently taking carnosine supplements
  • Unable to provide a urine sample (anuric)
  • Pregnant participants
  • Using dual antiplatelet therapies (exclusion from biopsy)
  • Internal metal objects preventing MRI or 1HMRS scans

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

University of Louisville School of Medicine, Department of Medicine, Division of Environmental Medicine

Louisville, Kentucky, United States, 40202

Actively Recruiting

2

University Surgical Associates, 401 E. Chestnut St, Suite 710

Louisville, Kentucky, United States, 40202

Not Yet Recruiting

3

UofL Physicians - Vascular Surgery Associates, 201 Abraham Flexner Way, Suite 1004

Louisville, Kentucky, United States, 40202

Not Yet Recruiting

Loading map...

Research Team

S

Shahid Baba, PhD

CONTACT

A

Amit Dwivedi, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Effects of Carnosine In Patients With Peripheral Arterial Disease Patients | DecenTrialz